Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Healthtrust
McKinsey
Cantor Fitzgerald
Dow
Mallinckrodt
Deloitte
Cerilliant
Johnson and Johnson

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,842,282

« Back to Dashboard

Which drugs does patent 7,842,282 protect, and when does it expire?

Patent 7,842,282 protects VARITHENA and is included in one NDA.

This patent has twelve patent family members in ten countries.
Summary for Patent: 7,842,282
Title:Generation of therapeutic microfoam
Abstract: A method for producing a microfoam suitable for use in scleropathy of blood vessels comprises introducing a physiologically acceptable blood-dispersible gas into a container (1) holding an aqueous sclerosant liquid and releasing the mixture of blood-dispersible gas and sclerosant liquid, whereby upon release of the mixture the components of the mixture interact to form a microfoam.
Inventor(s): Harman; Anthony David (Henley-on-Thames, GB), Harper; Paul (Buckinghamshire, GB), Pollock; Neil (Hertfordshire, GB), Sinclair; Gary Stewart (Suffolk, GB)
Assignee: BTG International Limited (London, GB)
Application Number:11/580,020
Patent Claim Types:
see list of patent claims
Use; Formulation; Device;

Drugs Protected by US Patent 7,842,282

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,842,282

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0028692.2Nov 24, 2000

Non-Orange Book US Patents Family Members for Patent 7,842,282

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,842,283 Generation of therapeutic microfoam ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Mallinckrodt
Healthtrust
Merck
Baxter
Fuji
Fish and Richardson
Queensland Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.